Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02759588
Recruitment Status : Recruiting
First Posted : May 3, 2016
Last Update Posted : January 9, 2020
Information provided by (Responsible Party):
Genelux Corporation

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : November 2020